Hikma Pharmaceuticals (LON:HIK) Stock Price Down 14.1% – What’s Next?

Hikma Pharmaceuticals PLC (LON:HIK) dropped 14.1% on Thursday . The company traded as low as GBX 1,522 and last traded at GBX 1,522. Approximately 166,325,172 shares traded hands during trading, an increase of 7,989% from the average daily volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HIK. Berenberg Bank reduced their target price on Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating on the stock in a research report on Thursday, October 16th. Deutsche Bank Aktiengesellschaft lowered their price target on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. JPMorgan Chase & Co. reduced their target price on Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an “overweight” rating on the stock in a research report on Friday, August 8th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,600 price objective on shares of Hikma Pharmaceuticals in a report on Thursday, August 7th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of GBX 2,615.

Hikma Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The company has a fifty day moving average of GBX 1,734.94 and a two-hundred day moving average of GBX 1,896.07. The stock has a market capitalization of £3.37 billion, a P/E ratio of 9.11, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41.

Insiders Place Their Bets

In related news, insider Mazen Darwazah purchased 14,000 shares of the company’s stock in a transaction dated Tuesday, September 16th. The shares were acquired at an average cost of GBX 1,603 per share, with a total value of £224,420. Also, insider Laura Balan Balan bought 3,500 shares of the stock in a transaction on Friday, August 22nd. The shares were acquired at an average cost of GBX 1,821 per share, for a total transaction of £63,735. 17.77% of the stock is owned by corporate insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.